Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | CRHBP | P24387 | 1/20 | 0.34 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.34 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.31 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL370663 | 0.86 | HSD17B10 (0.36) | HSD17B10CYP3A4HPGDCRHBPCRHR2 | |
| SCHEMBL363406 | 0.82 | RAB9A (0.34) | HSD17B10CYP3A4HPGDCRHBPCRHR2 | |
| SCHEMBL17186974 | 0.82 | PLAU (0.40) | HSD17B10CYP3A4HPGDPDK2 | |
| SCHEMBL25206015 | 0.78 | PLAU (0.43) | HSD17B10 | |
| SCHEMBL29818360 | 0.78 | PLAU (0.43) | HSD17B10 | |
| SCHEMBL363834 | 0.78 | ALDH1A1 (0.37) | HSD17B10CYP3A4HPGDCRHBPCRHR2 | |
| SCHEMBL335733 | 0.76 | RECQL (0.35) | — | |
| SCHEMBL335550 | 0.74 | ALDH1A1 (0.37) | — | |
| SCHEMBL16175295 | 0.74 | MAPK1 (0.33) | HSD17B10CYP3A4HPGDCRHBPCRHR2 | |
| SCHEMBL17173641 | 0.72 | ALDH1A1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2593432-B1 | N-SULFONYLBENZAMIDE DERIVATIVES USEFUL AS VOLTAGE GATED SODIUM CHANNEL INHIBITORS | PFIZER LTD (GB) | 2014-10-22 | — | — | EP | disclosed |
| EP-2593432-B1 | N-SULFONYLBENZAMIDE DERIVATIVES USEFUL AS VOLTAGE GATED SODIUM CHANNEL INHIBITORS | PFIZER LTD (GB) | 2014-10-22 | — | — | EP | disclosed |
| US-8592629-B2 | Sulfonamide derivatives as Nav 1.7 inhibitors | PFIZER LIMITED (GB) | 2013-11-26 | — | — | US | disclosed |
| EP-2593432-A1 | N-SULFONYLBENZAMIDE DERIVATIVES USEFUL AS VOLTAGE GATED SODIUM CHANNEL INHIBITORS | Pfizer Limited (GB) | 2013-05-22 | — | — | EP | disclosed |
| WO-2012007861-A1 | N-SULFONYLBENZAMIDE DERIVATIVES USEFUL AS VOLTAGE GATED SODIUM CHANNEL INHIBITORS | PFIZER LIMITED (GB) | 2012-01-19 | — | — | WO | disclosed |
| WO-2012007861-A1 | N-SULFONYLBENZAMIDE DERIVATIVES USEFUL AS VOLTAGE GATED SODIUM CHANNEL INHIBITORS | PFIZER LIMITED (GB) | 2012-01-19 | — | — | WO | disclosed |
| US-20120010183-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2012-01-12 | — | — | US | disclosed |
| US-20120010183-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010183-A1 | Chemical Compounds | SCN1A, SCN1B, SCN7A | HSD17B10 1528/4885CYP3A4 471/4885HPGD 819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.